Stocks Health care NRSN
NASDAQ · Health careNeuroSense Therapeutics Ltd. (NRSN)
It posted a net loss of $11.1M. In fiscal 2025 capital spending exceeded operating cash flow by $7.7M. At December 31, 2025 it held $166K in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 31, 2026.
What NeuroSense Therapeutics Ltd. does
NeuroSense Therapeutics Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NRSN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$11.1M | -$0.44 | -$7.7M |
| 2024 | n/a | -$10.2M | -$0.54 | -$10.1M |
| 2023 | n/a | -$10.1M | -$0.74 | -$8.4M |
| 2022 | n/a | -$10.5M | -$0.91 | -$7.7M |
| 2021 | n/a | -$4M | -$0.55 | -$1.6M |
| 2021 | n/a | -$2.8M | -$0.43 | -$704K |
Full financial statements: income, balance sheet and cash flow
Dividends
It paid out $310K in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2023 | n/a | $310K | n/a |
| 2022 | n/a | $310K | n/a |
| 2021 | n/a | $29K | n/a |
| 2021 | n/a | $28K | n/a |
| 2019 | n/a | $27K | n/a |
Latest SEC filings
What NeuroSense Therapeutics Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 9, 2026
- August 27, 2026
- August 13, 2026
- August 6, 2026
- July 31, 2026
- July 31, 2026
- July 30, 2026Form F-3/A filing F-3/A
- July 22, 2026
- June 29, 2026
Insider trades
What the people running NeuroSense Therapeutics Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 16, 2026 | Eisenberg OrChief Financial Officer | Bought | 250,000 | $200K |
| June 16, 2026 | Ben-Noon AlonChief Executive Officer | Bought | 250,000 | $200K |
Who owns NRSN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Rimon Gold Assets Ltd.13G, passive with 2 related filers | 9.99% | December 9, 2024 |
Largest institutional holders
Insiders
2 insiders reported holding 6,038,283 shares in total, about $42M at the last price.
| Holder | Shares |
|---|---|
| Ben-Noon AlonChief Executive Officer | 4,534,233 |
| Eisenberg OrChief Financial Officer | 1,504,050 |
Questions about NRSN
What does NeuroSense Therapeutics Ltd. do?
NeuroSense Therapeutics Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NRSN.
Is NeuroSense Therapeutics Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $11.1M.
When did NeuroSense Therapeutics Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 25, 2026.
Similar companies
Compare NRSN with
Follow NRSN
Get an email when NeuroSense Therapeutics Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow NRSN: get an email when it filesWhere the numbers come from
Financial figures are the values NeuroSense Therapeutics Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.